<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00953199</url>
  </required_header>
  <id_info>
    <org_study_id>Lidocaine</org_study_id>
    <nct_id>NCT00953199</nct_id>
  </id_info>
  <brief_title>Topical Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis</brief_title>
  <official_title>A Single Center, Randomized, Double-Blind Controlled Study of Topical Endoluminal Pancreatic Duct Lidocaine for Prevention of Post-ERCP Pancreatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abraham Mathew MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if lidocaine is effective in reducing the incidence
      of post-ERCP pancreatitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Post endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis is a common cause of
      morbidity for which there is no known pharmacologic prophylaxis. Post-ERCP pancreatitis is
      thought to be caused by several factors, including intraductal pressure, multiple duct
      injections with contrast, and neural arc reflexes. Lidocaine is a safe, inexpensive class IV
      antiarrhythmic that has topical anesthetic effects, inhibits trypsin activity, and may
      potentially prevent post-ERCP pancreatitis by injection directly into the pancreatic duct at
      the time of ERCP. Lidocaine has been shown to inhibit phospholipase A2, a key pancreatic
      enzyme, interrupt local arc reflexes to stop neuronal transmission, and to dampen GI tract
      mucosal reflexes to prevent high ductal pressure.

      The key objective of this study is to determine if injection of lidocaine is beneficial in
      preventing post-ERCP pancreatitis. Subjects will be randomized to study group or control
      group in an equal ratio. The physicians performing the ERCP will be unaware of the treatment
      group to which patients have been assigned. Study arm will receive contrast agent Diatrizoate
      60% (5 ml) diluted with lidocaine 2% (5 ml) during ERCP. Control arm will receive contrast
      agent Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) during ERCP. Diatrizoate
      diluted with normal saline is the standard of care. Patients will be contacted 1 day and 1
      week post-ERCP to assess for symptoms of pancreatitis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post ERCP Pancreatitis is the Primary Outcome.</measure>
    <time_frame>24-48 hours post-procedure</time_frame>
    <description>The primary outcome of interest will be development of acute pancreatitis defined as new or worsening abdominal pain post-ERCP associated with an increase in serum amylase at least 3 times the upper limit of normal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum Amylase Levels</measure>
    <time_frame>measurement is taken 2 hrs after ERCP</time_frame>
    <description>serum amylase levels are measure by a blood draw</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">506</enrollment>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine Hydrochloride</intervention_name>
    <description>1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).</description>
    <arm_group_label>Normal Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients included are &gt;18 years old, referred to Endoscopy Clinic for an ERCP for any
             well established indication such as: biliary strictures, benign and malignant
             hepato-pancreato-biliary tumors, chronic pancreatitis, and suspected sphincter of Oddi
             dysfunction

        Exclusion Criteria:

          -  Known sensitivity to lidocaine or contrast agent

          -  History of seizure disorder

          -  History of cardiac arrhythmia (tachyarrhythmia, bradyarrhythmia, cardiac conduction
             defects, prolonged QT syndrome)

          -  History of congestive heart failure

          -  Active acute pancreatitis before procedure

          -  Planned biliary stent removal without pancreatogram

          -  Pregnancy

          -  Incarcerated individuals

          -  Less than 18 years of age

          -  Previous sphincterotomy

          -  Inability to give informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abraham Mathew, M.D., M.S.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Penn State College of Medicine, Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cosen-Binker LI, Binker MG, Negri G, Tiscornia O. Acute pancreatitis possible initial triggering mechanism and prophylaxis. Pancreatology. 2003;3(6):445-56. Epub 2003 Nov 19.</citation>
    <PMID>14631103</PMID>
  </reference>
  <reference>
    <citation>Kiyonari Y, Nishina K, Mikawa K, Maekawa N, Obara H. Lidocaine attenuates acute lung injury induced by a combination of phospholipase A2 and trypsin. Crit Care Med. 2000 Feb;28(2):484-9.</citation>
    <PMID>10708188</PMID>
  </reference>
  <reference>
    <citation>Mäkelä A, Kuusi T, Schröder T. Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro. Scand J Clin Lab Invest. 1997 Aug;57(5):401-7.</citation>
    <PMID>9279965</PMID>
  </reference>
  <reference>
    <citation>Portiansky EL, González PH. Protective effect of lidocaine in the experimental foot-and-mouth disease pancreatitis. Experientia. 1995 Nov 15;51(11):1060-2.</citation>
    <PMID>7498445</PMID>
  </reference>
  <reference>
    <citation>Schröder T, Kinnunen PK, Lempinen M. Xylocaine treatment in experimental pancreatitis in pigs. Scand J Gastroenterol. 1978;13(7):863-5.</citation>
    <PMID>725507</PMID>
  </reference>
  <reference>
    <citation>Schwartz JJ, Lew RJ, Ahmad NA, Shah JN, Ginsberg GG, Kochman ML, Brensinger CM, Long WB. The effect of lidocaine sprayed on the major duodenal papilla on the frequency of post-ERCP pancreatitis. Gastrointest Endosc. 2004 Feb;59(2):179-84.</citation>
    <PMID>14745389</PMID>
  </reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2009</study_first_submitted>
  <study_first_submitted_qc>August 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2009</study_first_posted>
  <results_first_submitted>January 19, 2017</results_first_submitted>
  <results_first_submitted_qc>September 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2017</results_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Abraham Mathew MD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>endoscopic retrograde cholangiopancreatography</keyword>
  <keyword>ERCP</keyword>
  <keyword>pancreatitis</keyword>
  <keyword>lidocaine</keyword>
  <keyword>post-ERCP pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>March 2010 -May 2013, recruited from the endoscopy unit</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Lidocaine</title>
          <description>Lidocaine Hydrochloride: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.</description>
        </group>
        <group group_id="P2">
          <title>Normal Saline</title>
          <description>Normal Saline: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="254"/>
                <participants group_id="P2" count="252"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Adult patients send for ERCP with a chance of contrast injection into the pancreatic duct</population>
      <group_list>
        <group group_id="B1">
          <title>Lidocaine</title>
          <description>Lidocaine Hydrochloride: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.</description>
        </group>
        <group group_id="B2">
          <title>Normal Saline</title>
          <description>Normal Saline: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="254"/>
            <count group_id="B2" value="252"/>
            <count group_id="B3" value="506"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56" lower_limit="18" upper_limit="99"/>
                    <measurement group_id="B2" value="55.6" lower_limit="19" upper_limit="92"/>
                    <measurement group_id="B3" value="55.8" lower_limit="18" upper_limit="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="128"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="254"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="126"/>
                    <measurement group_id="B3" value="252"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post ERCP Pancreatitis is the Primary Outcome.</title>
        <description>The primary outcome of interest will be development of acute pancreatitis defined as new or worsening abdominal pain post-ERCP associated with an increase in serum amylase at least 3 times the upper limit of normal.</description>
        <time_frame>24-48 hours post-procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Lidocaine Hydrochloride: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>Normal Saline: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).</description>
          </group>
        </group_list>
        <measure>
          <title>Post ERCP Pancreatitis is the Primary Outcome.</title>
          <description>The primary outcome of interest will be development of acute pancreatitis defined as new or worsening abdominal pain post-ERCP associated with an increase in serum amylase at least 3 times the upper limit of normal.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>We calculated the sample size to be 570 in each arm, providing 80% power, allocation 1:1, two-sided, alpha 0.05, withdrawal rate of 3% and a reduction in pancreatitis from 8% to 4%. Randomization is performed with permuted blocks of 20. Analysis is based on intention to treat.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.45</p_value>
            <p_value_desc>.05 was set as level of significance</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Amylase Levels</title>
        <description>serum amylase levels are measure by a blood draw</description>
        <time_frame>measurement is taken 2 hrs after ERCP</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Lidocaine</title>
            <description>Study subjects receive a 1:1 combination of 5 ml Diatrizoate 60% and 5 ml Lidocaine Hydrochloride 2%
Lidocaine Hydrochloride: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.</description>
          </group>
          <group group_id="O2">
            <title>Normal Saline</title>
            <description>The control arm receives a 1:1 combination of 5 ml Diatrizoate and 5ml saline.
Normal Saline: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Amylase Levels</title>
          <description>serum amylase levels are measure by a blood draw</description>
          <units>units/liter</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="254"/>
                <count group_id="O2" value="252"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" lower_limit="30" upper_limit="1826"/>
                    <measurement group_id="O2" value="128" lower_limit="30" upper_limit="4000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over 48 hrs. Patients are observed in the recovery area until they are discharged after ERCP or admitted, usually about 2-3 hrs. They are called after 24 -48 hrs and later after a week for follow up.</time_frame>
      <desc>Pancreatitis and its symptoms were the study outcomes and not considered here as a separate adverse event</desc>
      <group_list>
        <group group_id="E1">
          <title>Lidocaine</title>
          <description>Lidocaine Hydrochloride: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.</description>
        </group>
        <group group_id="E2">
          <title>Normal Saline</title>
          <description>Normal Saline: 1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="254"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="252"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Abraham Mathew MD</name_or_title>
      <organization>Penn State Hershey Medical center</organization>
      <phone>717 531 3834</phone>
      <email>amathew@hmc.psu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

